Hypoglycemia medical therapy

Revision as of 14:42, 17 July 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Hypoglycemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoglycemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoglycemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoglycemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoglycemia medical therapy

CDC on Hypoglycemia medical therapy

Hypoglycemia medical therapy in the news

Blogs on Hypoglycemia medical therapy

Directions to Hospitals Treating Hypoglycemia

Risk calculators and risk factors for Hypoglycemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Asymptomatic:[1] 

  • Cases with blood glucose of ≤70 mg/dL with regular monitoring.
  • Repeating the measurement in short time.
  • Avoiding critical tasks.
  • Ingesting carbohydrates.
  • adjusting the regimen to avoid other attacks.

Symptomatic:[2]

  • Patients should have source of carbohydrates available all times.
  • 20 grams is usually sufficient to raise the blood glucose.
  • In patients taking alpha-glucosidase inhibitor (acarbose), only dextrose should be used to treat hypoglycemia becuase acarbose slowes digestion of carbohydrates.

Severe: 

  • A subcutaneous or intramuscular injection of 0.5 to 1.0 mg of glucagon will correct hypoglycemia within 15 minutes.
  • If failed this attempt or in severe cases, 25% or 50% dextrose intravenously (IV) followed by subcutaneous glucose.
  • If these measures aren't available:
  • Squeezing a glucose gel in the space between the teeth and buccal mucosa with patient head tilted on side to prevent aspiration.
  • If glucose gel isn't available, putting table sugar under the tongue may save patient.[3]
  • Hypoglycemia due to hormone deficiencies such as hypopituitarism or adrenal insufficiency usually ceases when the appropriate hormone is replaced.
  • Patients with diabetes history who has loss of consciousness and there is no method to determine nature of coma; hypoglycemi or hyperglycemia,then glucose should be given empirically. This will correct hypoglycemia and will not be particularly dangerous if blood glucose concentration is high.
  • Intranasal glucagon was effective in treating insulin-induced hypoglycemia in adults with type 1 diabetes in some studies but it is still under investigation.[4]

Postprandial hypoglycemia:

  • Frequent (every three hours) small meals or snacks.
  • Foods high in fiber, avoiding foods high in sugar.
  • Regular exercise regimen have been recommended.

Insulinoma:

Surgery is the best treatment for insulinoma and other pancreatic masses but if multiple metastases or bad general condition medical therapy is accepted:

  • Diazoxide prevents insulin secretion.[5]
  • Octreotide an analog of somatostatin inhibits the secretion of insulin and glucagon.[6] In patients with failed diazoxide attempts.
  • Everolimus, an inhibitor of the mammalian is option for refractory cases.

References

  1. Cryer PE (2009). "Preventing hypoglycaemia: what is the appropriate glucose alert value?". Diabetologia. 52 (1): 35–7. doi:10.1007/s00125-008-1205-7. PMID 19018509.
  2. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L; et al. (2013). "Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society". Diabetes Care. 36 (5): 1384–95. doi:10.2337/dc12-2480. PMC 3631867. PMID 23589542.
  3. Graz B, Dicko M, Willcox ML, Lambert B, Falquet J, Forster M; et al. (2008). "Sublingual sugar for hypoglycaemia in children with severe malaria: a pilot clinical study". Malar J. 7: 242. doi:10.1186/1475-2875-7-242. PMC 2605470. PMID 19025610.
  4. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL; et al. (2016). "Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study". Diabetes Care. 39 (2): 264–70. doi:10.2337/dc15-1498. PMC 4722945. PMID 26681725.
  5. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ; et al. (2005). "Malignant insulinoma: spectrum of unusual clinical features". Cancer. 104 (2): 264–72. doi:10.1002/cncr.21179. PMC 4136659. PMID 15937909.
  6. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E; et al. (2001). "Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours". Eur J Cancer. 37 (8): 1014–9. PMID 11334727.


Template:WikiDoc Sources